I agree with you Kenny. If there is a reasonable chance of completing the study and getting approval then I believe the company should stick it out - maybe add an additional study with recell as adjunct to other graft treatment and run the 2 in parallel, but Dolce and maybe others seem to think the current study should have been stopped and that the ceo's major failing was not having stopped the study. Maybe. but that is a costly (time and money) proposition.
I agree with you Kenny. If there is a reasonable chance of...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.14 |
Change
0.140(4.67%) |
Mkt cap ! $213.8M | |||
| Open | High | Low | Value | Volume |
| $3.08 | $3.17 | $3.08 | $922.4K | 295.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1432 | $3.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.14 | 107 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| AVH (ASX) Chart |